Trial Profile

Open-Label, Single-Center, Randomized, 2-way Crossover Study Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline (the Zen Study)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varenicline (Primary) ; Varenicline
Indications COVID 2019 infections; Dry eyes; Neurotrophic keratopathy
Focus Pharmacokinetics
Acronyms ZEN
Sponsors Oyster Point Pharmaceuticals

Most Recent Events

26 Aug 2021 Results published in the Clinical Therapeutics
05 Aug 2020 According to an Oyster Point Pharma media release, based on this study and other two trials (ZEN and ONSET-1) the NDA submission is expected in the fourth quarter of 2020.
05 Feb 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com